Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Gestational Trophoblastic Disease Market Forecast: What Value Will The Market Reach By 2030?
The gestational trophoblastic disease market has experienced consistent expansion in recent years. This market is projected to expand from $2.16 billion in 2025 to $2.26 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 4.6%. Historically, this expansion has been driven by progress in gynecologic oncology, the accessibility of hcg testing, wider acceptance of surgical treatments, heightened understanding of uncommon pregnancy-related conditions, and the implementation of clinical oncology protocols.
The market for gestational trophoblastic disease is projected to experience substantial growth in the upcoming years. It is anticipated to reach a valuation of $2.81 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 5.7%. This expansion during the projection period can be attributed to several factors, including enhanced diagnostic precision, the proliferation of oncology centers, the establishment of standardized treatment protocols, greater accessibility to healthcare, and a heightened emphasis on managing rare diseases. Key developments expected during the forecast timeframe encompass more effective hcg-based disease monitoring, an increasing adoption of chemotherapy for gtd management, a stronger emphasis on prompt diagnosis, the expansion of specialized women’s oncology services, and enhanced post-treatment follow-up.
Get A Free Sample Report With In-Depth Market Insights:
Gestational Trophoblastic Disease Market Opportunity Drivers: What’s Unlocking New Revenue Potential?
A future increase in infertility rates is anticipated to drive expansion in the gestational trophoblastic disease market. Infertility rates quantify the percentage of a population (couples or individuals) unable to achieve natural conception following 12 months of consistent, unprotected sexual activity. The rise in infertility is largely attributed to older maternal and paternal ages, since advanced reproductive age links to diminished egg and sperm quality, lower fertility, and increased conception complications. While usually a disease, gestational trophoblastic disease can offer unexpected understanding for infertility therapies by revealing the functions of trophoblastic tissue in implantation and hormone control, thus informing strategies to enhance conception success. For example, in April 2023, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported that around 17.5% of adults worldwide, or approximately 1 in 6 individuals, experience infertility, underscoring the urgent necessity for better access to cost-effective, high-quality fertility treatment for impacted persons. Consequently, the increasing incidence of infertility is fueling the gestational trophoblastic disease market. A future increase in cigarette smoking is projected to boost the expansion of the gestational trophoblastic disease market. Cigarette smoking involves igniting tobacco and breathing in the smoke, which holds numerous chemicals and toxins capable of harming various bodily structures. This habit could damage the DNA within trophoblastic cells, vital for placenta formation, potentially causing their abnormal growth and division, thus leading to gestational trophoblastic disease. For example, in October 2024, the European Respiratory Society’s (ERS), a Switzerland-based non-profit organization, published a study on youth smoking trends, indicating a substantial increase in rates, from 22.5% of respondents smoking in 2022 to 40.1% in 2024. Hence, the rise in cigarette smoking is stimulating the gestational trophoblastic disease market.
Gestational Trophoblastic Disease Market Segment Outlook: Which Categories Are Growing Fastest?
The gestational trophoblastic disease market covered in this report is segmented –
1) By Type: Hydatidiform Mole, Choriocarcinoma, Placental-Site Trophoblastic Tumor, Epithelioid Trophoblastic Tumor, Other Types
2) By Treatment: Surgery, Chemotherapy, Suction Dilation And Curettage (D&C), Radiation Therapy
3) By End User: Hospital And Clinics, Diagnostic Centers, Other End Users
Subsegments:
1) By Hydatidiform Mole: Complete Hydatidiform Mole, Partial Hydatidiform Mole
2) By Choriocarcinoma: Non-Metastatic Choriocarcinoma, Metastatic Choriocarcinoma
3) By Placental-Site Trophoblastic Tumor: PSTT With Normal Placentation, PSTT With Abnormal Placentation
4) By Epithelioid Trophoblastic Tumor: Epithelioid Trophoblastic Tumor With No Evidence Of Metastasis, Epithelioid Trophoblastic Tumor With Metastasis
5) By Other Types: Trophoblastic Tumor Of Unknown Origin, Non-Gestational Trophoblastic Neoplasia
Gestational Trophoblastic Disease Market Leading Companies And Competitive Benchmarking
Major companies operating in the gestational trophoblastic disease market are Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Novartis AG, Merck And Co. Inc., Sun Pharmaceutical Industries Ltd., GSK plc, Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca plc, Eli Lilly and Company, Daiichi Sankyo Co. Ltd., Eisai Co. Ltd.
View The Full Gestational Trophoblastic Disease Market Report:
Gestational Trophoblastic Disease Market Largest Region: Which Geography Holds The Biggest Share?
Asia-Pacific was the largest region in the gestational trophoblastic disease market in 2025, and is expected to be the fastest-growing region in the forecast period. The regions covered in the gestational trophoblastic disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
